A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

Summary

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.

A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.

The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.

Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.

The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.

Conditions

• Liver Cirrhoses
• Hepatocellular Carcinoma (HCC)
• Sarcopenia in Liver Cirrhosis
• Portal Hypertension Related to Cirrhosis
• MRI
• Ultrasound

Sponsors & Collaborators

• Antaros Medical

  collaborator INDUSTRY

• Amra Medical AB

  collaborator INDUSTRY

• Region Östergötland

  collaborator OTHER

• Region Jönköping County

  collaborator OTHER_GOV

• Västra Götalandsregionen

  collaborator OTHER

• Region Stockholm

  collaborator OTHER_GOV

• Örebro County Council

  collaborator OTHER_GOV

• Uppsala County Council, Sweden

  collaborator OTHER_GOV

• Norrlands Universitetssjukhus, Umea, Sweden

  collaborator UNKNOWN

• Mattias Ekstedt

  lead OTHER_GOV

Principal Investigators

• Mattias Ekstedt, MD, PhD · Linkoeping University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-18

Primary Completion

2029-12-31

Completion

2031-12-31

Countries

• Sweden

Study Locations